We are happy to consider partnerships for joint investigation of genetic cohorts for complex stratification and to extract targets of high potential clinical value.
We are happy to apply the Nomaly technology and other computational analyses exclusively to your genetic cohort.
If you are interested in licensing the Nomaly technology non-exclusively, and non-competing to our activities, then please contact us.
We are currently open to investor enquiries regarding the remaining availability in our seed round, aiming to close by end of Q1 2025.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.